1011 related articles for article (PubMed ID: 27084740)
1. The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition.
Hegde PS; Karanikas V; Evers S
Clin Cancer Res; 2016 Apr; 22(8):1865-74. PubMed ID: 27084740
[TBL] [Abstract][Full Text] [Related]
2. LIGHT May Improve Immune Checkpoint Blockade Response.
Cancer Discov; 2016 Jun; 6(6):OF9. PubMed ID: 27080334
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Chen PL; Roh W; Reuben A; Cooper ZA; Spencer CN; Prieto PA; Miller JP; Bassett RL; Gopalakrishnan V; Wani K; De Macedo MP; Austin-Breneman JL; Jiang H; Chang Q; Reddy SM; Chen WS; Tetzlaff MT; Broaddus RJ; Davies MA; Gershenwald JE; Haydu L; Lazar AJ; Patel SP; Hwu P; Hwu WJ; Diab A; Glitza IC; Woodman SE; Vence LM; Wistuba II; Amaria RN; Kwong LN; Prieto V; Davis RE; Ma W; Overwijk WW; Sharpe AH; Hu J; Futreal PA; Blando J; Sharma P; Allison JP; Chin L; Wargo JA
Cancer Discov; 2016 Aug; 6(8):827-37. PubMed ID: 27301722
[TBL] [Abstract][Full Text] [Related]
4. Reversing T-cell Dysfunction and Exhaustion in Cancer.
Zarour HM
Clin Cancer Res; 2016 Apr; 22(8):1856-64. PubMed ID: 27084739
[TBL] [Abstract][Full Text] [Related]
5. Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era.
Linette GP; Carreno BM
Curr Hematol Malig Rep; 2019 Aug; 14(4):286-291. PubMed ID: 31187421
[TBL] [Abstract][Full Text] [Related]
6. Translating Pembrolizumab to Clinical Practice: Speak Immunology and Learn Fast!
van Elsas A; van Eenennaam H; Haanen JB
Clin Cancer Res; 2015 Oct; 21(19):4251-3. PubMed ID: 26169966
[TBL] [Abstract][Full Text] [Related]
7. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Shin DS; Ribas A
Curr Opin Immunol; 2015 Apr; 33():23-35. PubMed ID: 25621841
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies.
Ring KL; Pakish J; Jazaeri AA
Cancer J; 2016; 22(2):101-7. PubMed ID: 27111905
[TBL] [Abstract][Full Text] [Related]
9. Targeting novel inhibitory receptors in cancer immunotherapy.
Ding QQ; Chauvin JM; Zarour HM
Semin Immunol; 2020 Jun; 49():101436. PubMed ID: 33288379
[TBL] [Abstract][Full Text] [Related]
10. Advancing Immunotherapy in Metastatic Breast Cancer.
Mansour M; Teo ZL; Luen SJ; Loi S
Curr Treat Options Oncol; 2017 Jun; 18(6):35. PubMed ID: 28534250
[TBL] [Abstract][Full Text] [Related]
11. Emerging Opportunities and Challenges in Cancer Immunotherapy.
Whiteside TL; Demaria S; Rodriguez-Ruiz ME; Zarour HM; Melero I
Clin Cancer Res; 2016 Apr; 22(8):1845-55. PubMed ID: 27084738
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
Duan J; Wang Y; Jiao S
Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models.
Hekim C; Ilander M; Yan J; Michaud E; Smykla R; Vähä-Koskela M; Savola P; Tähtinen S; Saikko L; Hemminki A; Kovanen PE; Porkka K; Lee FY; Mustjoki S
Cancer Immunol Res; 2017 Feb; 5(2):157-169. PubMed ID: 28073775
[TBL] [Abstract][Full Text] [Related]
14. A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells.
Kareva I
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29027915
[TBL] [Abstract][Full Text] [Related]
15. Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice.
Ueha S; Yokochi S; Ishiwata Y; Ogiwara H; Chand K; Nakajima T; Hachiga K; Shichino S; Terashima Y; Toda E; Shand FH; Kakimi K; Ito S; Matsushima K
Cancer Immunol Res; 2015 Jun; 3(6):631-40. PubMed ID: 25711759
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.
Terranova-Barberio M; Thomas S; Munster PN
Immunotherapy; 2016 Jun; 8(6):705-19. PubMed ID: 27197539
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control.
Schoenhals JE; Seyedin SN; Tang C; Cortez MA; Niknam S; Tsouko E; Chang JY; Hahn SM; Welsh JW
Cancer J; 2016; 22(2):130-7. PubMed ID: 27111909
[TBL] [Abstract][Full Text] [Related]
18. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.
Galluzzi L; Buqué A; Kepp O; Zitvogel L; Kroemer G
Cancer Cell; 2015 Dec; 28(6):690-714. PubMed ID: 26678337
[TBL] [Abstract][Full Text] [Related]
19. Chemokines and cancer: new immune checkpoints for cancer therapy.
Karin N
Curr Opin Immunol; 2018 Apr; 51():140-145. PubMed ID: 29579623
[TBL] [Abstract][Full Text] [Related]
20. Wogonin Inhibits Tumor-derived Regulatory Molecules by Suppressing STAT3 Signaling to Promote Tumor Immunity.
Xiao W; Wu K; Yin M; Han S; Ding Y; Qiao A; Lu G; Deng B; Bo P; Gong W
J Immunother; 2015 Jun; 38(5):167-84. PubMed ID: 25962106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
